ClinicalTrials.Veeva

Menu

The Effect of Enhanced Recovery After Surgery (ERAS) for Cesarean Section on Neonatal Blood Glucose

University of Arizona logo

University of Arizona

Status

Enrolling

Conditions

Cesarean Section
Enhanced Recovery After Surgery

Treatments

Dietary Supplement: Carbohydrate Preoperative Drink

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05081804
ERAS-CS

Details and patient eligibility

About

Enhanced Recovery After Surgery (ERAS) is a set of evidence-based guidelines that may be used during perioperative care for cesarean section. While there is good evidence that following ERAS protocols benefits postoperative recovery, less is understood about the effect on the fetus and neonate. This will be a randomized equivalence trial to determine if drinking a carbohydrate rich drink prior to cesarean section has an effect on neonatal glucose.

Full description

Cesarean section is one of the most common surgeries performed today with over one million performed in the United States annually. Enhanced Recovery After Surgery (ERAS) is a standardized set of guidelines which has been utilized in multiple surgical disciplines, including colorectal, urologic, gynecologic, and hepatobiliary surgery. ERAS guidelines are now being adopted for the obstetric population and provide evidence-based guidelines for perioperative care for cesarean delivery. Part of the preoperative ERAS pathway includes the recommendation for oral administration of a carbohydrate- containing fluid prior to surgery. A Cochrane review found that across several trials, carbohydrate loading was associated with favorable outcomes such as decreased time to passage of gas and reduction in length of hospital stay. Maternal outcomes are improved due to the decrease in insulin resistance that perioperative carbohydrate loading provides. During surgery, the body enters a catabolic state leading to insulin resistance that may delay recovery. Preoperative carbohydrate drinks have also been given to patients with diabetes, and although the decrease in insulin resistance is less certain, there seems to be less risk of postoperative hyperglycemia and the practice is considered safe but needing more study.

While it is clear that ERAS provides benefits to the mother, less is understood about the effects on the fetus and neonate. Fetal and neonatal glucose level is known to be strongly tied to the level of insulin resistance and glucose level in the mother, particularly in the immediate time period prior to birth. Neonatal hypoglycemia after delivery is an important determinate of health, as hypoglycemia has been linked to poor neurologic outcomes. Cesarean section is a known risk factor for neonatal hypoglycemia requiring IV dextrose with an odds ratio of 1.4. There are known risk factors for neonatal hypoglycemia, such as being the infant of a diabetic mother, preterm, weight <2500g, or >4500g, and poor feeding, however, the incidence of hypoglycemia in neonates with no clear risk factors is 5-15%. With health care systems adopting the ERAS protocol as part of the standardized guidelines for perioperative care, it will be important to understand the effect of carbohydrate loading on both maternal and neonatal glucose levels as well as other outcomes.

Enrollment

216 estimated patients

Sex

Female

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Women with term pregnancies
  • Intact Amniotic membranes
  • Not in labor
  • Planned delivery by cesarean section
  • Fluent in either English or Spanish

Exclusion criteria

  • Less than 18 years old
  • In labor
  • Not fasted at least 8 hours
  • Did not do glucose screening during pregnancy
  • Fetal anomalies
  • History of galactosemia

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

216 participants in 4 patient groups

Non-diabetic Control
No Intervention group
Description:
Patients without diabetes. No intervention will be administered - standard care.
Non-diabetic CHO Drink
Experimental group
Description:
Patients without diabetes. Commercially available preoperative carbohydrate drink will be administered two hours prior to cesarean section.
Treatment:
Dietary Supplement: Carbohydrate Preoperative Drink
Diabetic Control
No Intervention group
Description:
Patients with diabetes. No intervention will be administered - standard care.
Diabetic CHO Drink
Experimental group
Description:
Patients with diabetes. Commercially available preoperative carbohydrate drink will be administered two hours prior to cesarean section.
Treatment:
Dietary Supplement: Carbohydrate Preoperative Drink

Trial contacts and locations

1

Loading...

Central trial contact

Karen Lesser, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems